These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19265600)

  • 1. [Influence of the reimbursement scheme on the consumption of drugs].
    Madsen UK
    Ugeskr Laeger; 2009 Mar; 171(10):783-6. PubMed ID: 19265600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Income related inequality in prescription drugs in Denmark.
    Gundgaard J
    Pharmacoepidemiol Drug Saf; 2005 May; 14(5):307-17. PubMed ID: 15508133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Physicians' experience with increased use of individual reimbursement for pharmaceuticals].
    Levorsen A; Kristiansen IS; Aasland OG
    Tidsskr Nor Laegeforen; 2008 Aug; 128(16):1829-32. PubMed ID: 18787593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reimbursement for drugs -- a register study comparing economic outcome for five healthcare centres in areas with different socioeconomic conditions.
    Semark B; Fredlund K; Astrand B; Brudin L
    Scand J Public Health; 2009 Aug; 37(6):647-53. PubMed ID: 19546143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Economic feasibility study and reimbursement rules--illustrated by a concrete example].
    Keiding H; Faergeman O
    Ugeskr Laeger; 2008 Feb; 170(8):651-4. PubMed ID: 18364159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in opioid consumption in the Nordic countries 2002-2006.
    Hamunen K; Paakkari P; Kalso E
    Eur J Pain; 2009 Oct; 13(9):954-62. PubMed ID: 19091608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden.
    Pettersson B; Hoffmann M; Wändell P; Levin LÅ
    Health Policy; 2012 Jan; 104(1):84-91. PubMed ID: 22115548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical pharmacology and the selection of drugs].
    Stanulović M
    Med Pregl; 1989; 42(11-12):391-4. PubMed ID: 2642196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Social status affects drug costs and health care costs. A registry study shows that Care Choice should take socioeconomic factors into account].
    Engström S; Magnusson H; Enthoven P; Walter L; Thorell K; Halling A; Borgquist L
    Lakartidningen; 2009 Nov 25-Dec 1; 106(48):3248, 3250, 3252-3. PubMed ID: 20101836
    [No Abstract]   [Full Text] [Related]  

  • 11. [Biased criticism of drug reimbursement rules].
    Lindberg M
    Ugeskr Laeger; 2008 Apr; 170(15):1261; author reply 1261. PubMed ID: 18472464
    [No Abstract]   [Full Text] [Related]  

  • 12. [Priorisation in health-care; drug-reimbursement priorities in Hungary in 2004].
    Kárpati K; Brandtmüller A; Májer I; Gulácsi L
    Acta Pharm Hung; 2006; 76(4):191-9. PubMed ID: 17575799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influencing the prescriptions of general practitioners via guidelines and feedback--secondary publication].
    Schaefer K; Hansen AO; Maerkedahl H; Rehfeld C; Birk HO; Henriksen LO
    Ugeskr Laeger; 2008 Dec; 170(49):4030-2. PubMed ID: 19127691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Industry ponders reimbursement crisis.
    Bouchie A
    Nat Biotechnol; 2003 Apr; 21(4):347-8. PubMed ID: 12665810
    [No Abstract]   [Full Text] [Related]  

  • 16. [Preparations against stomach ulcer: use, prices and subsidy before and after 27 March 1989].
    Nissen A
    Ugeskr Laeger; 1991 May; 153(20):1436-7. PubMed ID: 2028558
    [No Abstract]   [Full Text] [Related]  

  • 17. [Economic feasibility study and reimbursement rules--illustrated by a concrete example].
    Kolenda K; Friis ML
    Ugeskr Laeger; 2008 Apr; 170(15):1257; author reply 1257. PubMed ID: 18472461
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased antimicrobial consumption following reimbursement reform in Turkey.
    Karabay O; Hosoglu S
    J Antimicrob Chemother; 2008 May; 61(5):1169-71. PubMed ID: 18272511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
    Barozzi N; Tett SE
    Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The market of synonymous preparations in Denmark 1985-1990. A comparison of prices and quantities on the market].
    Nissen A
    Ugeskr Laeger; 1991 Dec; 153(50):3558-62. PubMed ID: 1776198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.